Masimo (NASDAQ:MASI) Price Target Raised to $205.00

Masimo (NASDAQ:MASI) had its price target boosted by Wells Fargo & Company from $193.00 to $205.00 in a research note released on Wednesday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the medical equipment provider’s stock.

Several other equities analysts also recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday. Piper Sandler lifted their price objective on shares of Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Raymond James upped their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $194.80.

Masimo Price Performance

MASI opened at $190.34 on Wednesday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company’s 50-day moving average price is $172.56 and its 200 day moving average price is $152.84. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $191.10. The firm has a market cap of $10.19 billion, a price-to-earnings ratio of 131.27 and a beta of 1.02.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $600.70 million for the quarter, compared to analysts’ expectations of $593.35 million. As a group, sell-side analysts expect that Masimo will post 4.1 earnings per share for the current year.

Hedge Funds Weigh In On Masimo

A number of institutional investors and hedge funds have recently bought and sold shares of MASI. Jones Financial Companies Lllp acquired a new stake in shares of Masimo in the 4th quarter worth approximately $27,000. UMB Bank n.a. raised its holdings in Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 123 shares in the last quarter. Trust Co. of Vermont acquired a new stake in Masimo in the fourth quarter worth approximately $33,000. Blue Trust Inc. boosted its stake in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 64 shares during the period. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.